Paloma Partners’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Paloma Partners’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-4,602	Closed	-$27K	–	2259
2019 Q4	$27K	Buy	+4,602	New	+$25K	﹤0.01%	2095
2019 Q2	–	Sell	-10,589	Closed	-$211K	–	2279
2019 Q1	$211K	Buy	10,589 +29	+0.3%	+$506	0.01%	1494
2018 Q4	$139K	Buy	+10,560	New	+$211K	﹤0.01%	1098

Other funds holding KDNY

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Paloma Partners's KDNY Position: Q1 2020 in Review

Paloma Partners sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q1 2020, closing a stake of 4,602 shares — an estimated $27K sold.

Paloma Partners first reported a position in KDNY in Q4 2018 and held it in 3 quarters. The position peaked at $211K in Q1 2019. 82 funds tracked by Wall St. Rank hold KDNY as of Q1 2020.

Paloma Partners reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Paloma Partners sold 4,602 Chinook Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $27K.
Paloma Partners first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2018 and held it in 3 quarters.
Paloma Partners's Chinook Therapeutics, Inc. Common Stock position peaked at $211K in Q1 2019.
82 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Paloma Partners's 13F filing for Q1 2020, filed 15 May 2020.